Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Targeting the DUSP6-RSK1-S6 axis in myeloproliferative neoplasms and secondary acute myeloid leukemia.
FY 2021-22
Summary
Myeloproliferative neoplasms (MPNs) are a group of blood cancers/leukemias in which there is overproduction of one or more types of blood cells and affect ~5/100,000 persons. Polycythemia vera and essential thrombocythemia are MPNs characterized by elevated red blood cells and platelets, respectively, while myelofibrosis is a more aggressive subtype demonstrated by anemia, spleen enlargement, and bone marrow fibrosis. MPNs also exhibit a propensity for transformation to secondary acute myeloid leukemia (sAML), for which the prognosis is dismal (median survival < 6 months). Despite vigorous research, therapies capable of reliably halting or preventing MPN disease progression remain elusive. Thus, there is a pressing need to understand the mechanisms underlying this transformation process, which could translate to therapies capable of preventing and/or treating disease progression.
We have identified elevated expression of DUSP6, a cancer growth promoter, in cells from sAML patients, suggesting it may drive disease progression. I propose to better define its role and those of downstream effectors with goals of targeting these candidates therapeutically. First, I will assess consequences of both elevated DUSP6 expression and gene knockout in mouse cancers models by measuring hallmarks of disease in the development of bone marrow fibrosis, blood cancer counts, and survival outcomes. Second, elevated expression of downstream effector RSK1 is also associated with poorer survival in AML patients. I aim to repurpose a clinical-grade RSK1 inhibitor that is currently being evaluated in clinical trials for solid tumors to treat these blood cancers. Following, I will study inhibitor efficacy in suppressing cancer across leukemia mouse models and patient samples.
Collectively, the proposed studies will provide clarity in disease development and progression of MPN to AML and elucidate new therapeutic treatments for patients with blood cancers with a goal of a clinical trial.
Department
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Recipient
Location
Missouri, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
457143
Name
Kong Tim
Region
Missouri
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Targeting the DUSP6-RSK1-S6 axis in myeloproliferative neoplasms and secondary acute myeloid leukemia.
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Acute Myeloid Leukemia; Disease Transformation; Mass Cytometry; Multiomic Profiling; Myeloproliferative Neoplasms; Patient-Derived Xenograft Models; Targeted Therapies In Cancer
Abstract
Myeloproliferative neoplasms (MPNs) are a group of blood cancers/leukemias in which there is overproduction of one or more types of blood cells and affect ~5/100,000 persons. Polycythemia vera and essential thrombocythemia are MPNs characterized by elevated red blood cells and platelets, respectively, while myelofibrosis is a more aggressive subtype demonstrated by anemia, spleen enlargement, and bone marrow fibrosis. MPNs also exhibit a propensity for transformation to secondary acute myeloid leukemia (sAML), for which the prognosis is dismal (median survival < 6 months). Despite vigorous research, therapies capable of reliably halting or preventing MPN disease progression remain elusive. Thus, there is a pressing need to understand the mechanisms underlying this transformation process, which could translate to therapies capable of preventing and/or treating disease progression.
We have identified elevated expression of DUSP6, a cancer growth promoter, in cells from sAML patients, suggesting it may drive disease progression. I propose to better define its role and those of downstream effectors with goals of targeting these candidates therapeutically. First, I will assess consequences of both elevated DUSP6 expression and gene knockout in mouse cancers models by measuring hallmarks of disease in the development of bone marrow fibrosis, blood cancer counts, and survival outcomes. Second, elevated expression of downstream effector RSK1 is also associated with poorer survival in AML patients. I aim to repurpose a clinical-grade RSK1 inhibitor that is currently being evaluated in clinical trials for solid tumors to treat these blood cancers. Following, I will study inhibitor efficacy in suppressing cancer across leukemia mouse models and patient samples.
Collectively, the proposed studies will provide clarity in disease development and progression of MPN to AML and elucidate new therapeutic treatments for patients with blood cancers with a goal of a clinical trial.
Competitiondate
202110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kong, Tim
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~